Drug Trial Radar · NCT07137559
CELZ-201-DDT for the Treatment of Chronic Lower Back Pain
Last checked: Nov 20, 2026Latest source record: Aug 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Available
Enrollment
Not stated
Start
Not stated
Primary completion
Not stated
Sponsor
- Lead sponsor
- Creative Medical Technology Holdings IncIndustry
- Sponsor type
- Industry
- First posted
- Aug 22, 2025
Design
- Study type
- Expanded access
- Who can join
- All sexes, from 18 years, up to 80 years
Summary
As written by the sponsor on the registry.
CELZ-201-DDT is an investigational (experimental) cell therapy currently being studied for people with degenerative disc disease who have chronic lower back pain.
Conditions
- Chronic Back Pain
- Degenerative Disc Disease Lumbar
Interventions
CELZ-201-DDTDrug
CELZ-201-DDT is administered via intramuscular injection. Dosing, administration, and follow-up will be determined by the treating physician in accordance with the EA authorization and medical judgment. Safety monitoring will be performed during and after treatment, and all serious adverse events will be reported to the FDA and IRB per applicable regulations.
Primary outcomes
What the sponsor says the trial is designed to measure.
No primary outcomes listed.
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.